Mounjaro 2.5 mg Inj

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist, meaning it mimics two natural gut hormones that help regulate blood sugar, appetite, and digestion. By activating both pathways, it helps the body release insulin when blood sugar is high, while also reducing appetite and helping people feel fuller for longer. It is approved for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. It is also approved for chronic weight management in adults with obesity, or with overweight and a weight-related health condition, where clinical trials have shown substantial and sustained weight reduction. Administered as a convenient once-weekly subcutaneous injection using a prefilled pen, it is simple to use at home after training from a healthcare professional. Many patients also see improvements in related health markers such as blood pressure, cholesterol, and waist circumference. Treatment usually starts at a low dose that is gradually increased, helping the body adjust and allowing doctors to find the most suitable dose for each person. Its introduction has been regarded as a major advance in the management of diabetes and obesity, offering new hope to many patients. Regular follow-up with a healthcare provider helps track progress, support healthy lifestyle habits, and keep treatment on course. With appropriate medical guidance, Tirzepatide offers a powerful, well-supported option for improving metabolic health and overall quality of life.